Quaker City

Researchers are evaluating whether antiseptic-coated sutures reduce the risk of postoperative pancreatic fistulas compared to standard sutures in patients undergoing pancreatoduodenectomy, a surgery involving removal of parts of the pancreas and nearby organs. This randomized controlled trial aims to see if using antiseptic-coated sutures can lower the rate of clinically significant fistulas within 90 days after surgery. Participants will be randomly assigned to receive either standard non-antiseptic sutures or triclosanantiseptic-coated sutures during their pancreatoduodenectomy. The antiseptic-coated sutures, specifically Ethicon PDS Plus Antibacterial Sutures, will be used at the pancreatojejunostomy layer throughout the surgery. Both sutures are commonly used at the study center. Participants will be followed for up to 90 days after surgery to monitor for postoperative pancreatic fistulas and surgical site infections. Researchers will assess outcomes such as fistula rates, infection rates, hospital and ICU length of stay, and any interventions needed for fistulas. The total participation period involves surgery and a 90-day postoperative observation to evaluate safety and effectiveness measures.

Researchers are evaluating a new drug called visugromab in people with cancer-associated cachexia, a condition involving unintended weight loss seen in certain cancers like lung and bowel cancer. The study aims to find out if visugromab helps participants regain weight, improve appetite, and increase their ability to move. The research compares visugromab against a placebo to assess its effects and safety. Participants receive one of several doses of visugromab or a placebo through an intravenous drip every 4 weeks at a hospital or clinic. The study uses a randomized, double-blind design with multiple dose levels of visugromab, including low, medium, and high doses. Treatment continues with regular checkups and assessments. During the trial, participants will undergo tests and evaluations at each visit, including monitoring changes in body weight and appetite over 12 weeks. The study team will also observe any medical problems experienced while taking visugromab. Participation may last several months, with visits every 4 weeks for treatment and safety checks.